Introduction
============

Extramedullary plasmacytoma (EMP) is rare, accounting for approximately 3% of all plasma cell neoplasms. Up to 80% of EMP cases occur in the head and neck region, particularly in the upper aerodigestive tract, which constitutes less than 1% of head and neck tumors ([@b1-ol-0-0-8992],[@b2-ol-0-0-8992]). Most head and neck EMPs occur in the sinonasal region, and fewer are found in the larynx ([@b3-ol-0-0-8992],[@b4-ol-0-0-8992]). Although the primary cause of mortality is actually progression to multiple myeloma (MM), conversion to MM is uncommon (11--30% incidence). Here, we describe an individual with laryngeal EMP who developed acute myeloid leukemia (AML), rather than MM. Due to the rarity of this tumor, most previous studies focused on a case or case series. In an effort to describe this rare tumor accurately, we made a literature review about its clinical features, diagnosis, treatment modalities, outcomes, and potential sequelae of this disease.

Materials and methods
=====================

### Literature review

An electronic literature search was performed in PubMed using the following terms 'plasmacytoma', 'extramedullary plasmacytoma', 'plasma cell tumor' in combination with the terms 'larynx or head and neck'. Articles published from January 1948 to October 2017 were reviewed to identify cases of laryngeal EMP. Nonhuman, duplicates, and non-English language research were excluded. Abstracts were first reviewed to screen articles that discussed cases of laryngeal EMP, and then full-text articles were reviewed for extraction of data. References of the included studies were also examined for additional cases. Individual patient data were collected on age, sex, presentation, site of lesions, treatment course, long-term follow-up and outcomes. Meanwhile, articles for which individual patient data was not available or which focused solely on radiologic, histopathological findings, and diagnosis, were also excluded.

### Statistical analysis

All the recorded treatment modalities are classified in two main categories: Surgically based treatment including surgical resection either alone or with adjuvant radiotherapy, and no-surgically based treatment. Differences between the above two treatment modalities were analyzed by chi-square test. SPSS version 20 statistical software (IBM Corp., Chicago, Illinois) was used, and P\<0.05 was considered to indicate a statistically significant difference for all tests.

### Ethics statement

This study was approved by the ethics committee of the Second Xiangya Hospital, Central South University (Changsha, China). Written informed consent was obtained from the patient.

Results
=======

### The initial database search yielded 2,022 studies

The articles that were in non-English language, animal research, or duplicate articles were excluded, and 270 studies were left. Next, those unrelated abstracts such as solely focusing on imaging examination or histopathological findings were eliminated, and a total of 127 articles were left for further analysis. The articles in which full-text was unavailable or individual data was incomplete were ruled out. The bibliographies were also examined for additional cases. Finally, 70 studies comprising a total of 98 cases were left for analysis. Therefore, a total of 99 unique patients including our case were identified and the individual patient data collected are given in [Table I](#tI-ol-0-0-8992){ref-type="table"} ([@b5-ol-0-0-8992]--[@b71-ol-0-0-8992]). The clinical characteristics for the 99 patients included were summarized in [Table II](#tII-ol-0-0-8992){ref-type="table"}.

### Case presentation

A 46-year old male presented to our hospital with cough and sore throat of a 4 month duration. He had a history of hypothyroidism for more than 10 years and received a diagnosis of tuberculosis before presenting to our hospital, but his symptoms persisted after anti-tuberculosis treatment. Fiberoptic laryngoscopy showed swelling of the epiglottis and aryepiglottic fold ([Fig. 1](#f1-ol-0-0-8992){ref-type="fig"}). Laboratory findings showed an increased erythrocyte sedimentation rate, other examinations such as anti-tuberculosis antibody test and rheumatoid factors were normal. Chest X-ray was normal. Computed tomography (CT) and magnetic resonance imaging (MRI) of the neck revealed substantial swelling and edema of the epiglottis and enlargement of cervical lymph nodes. Biopsy of these two sites was performed under general anesthesia and microscopic observation showed many well-differentiated plasma cells and lymphocytes infiltration ([Fig. 2](#f2-ol-0-0-8992){ref-type="fig"}). Immunohistochemical staining of the laryngeal specimen showed the most cells were positive for CD79a, CD138, CD38, CD5, Ki67, and Lambda, whereas negative for CD20, CD3, CD45RO, Cyclin D1, and PAX-5. Immunohistochemical staining of the cervical lymph nodes showed the most cells were positive for CD38, CD138, CD79a, CD45RO, CD31, Ki67, CD68 and LgG. Gene rearrangement studies indicated monoclonal rearrangements of the immunoglobulin heavy chain. A diagnosis of EMP of the larynx was made and a series of examinations were performed to exclude MM. Laboratory examinations including blood protein electrophoresis, serum immunoglobulins, urinary tests for Bence-Jones proteins were normal. Report of bone marrow biopsy was also within the normal range. In addition to cervical lymphadenopathy, PET-CT and other imaging examinations such as CT and MRI of the chest, abdomen and pelvis showed no distant metastasis. Complete surgical resection was not suitable for this patient, so, he was referred to the Hematology-Oncology Department, and received radiotherapy including 25 sessions of 55 Gy for laryngeal lesion and cervical metastasis. Meanwhile, adjuvant chemotherapy was also given with thalidomide, vincristine, epirubicin, and cyclophosphamide. His symptoms disappeared after treatment and he had monthly follow-ups.

Five years later, he was readmitted with dizziness that lasted 2 weeks. Complete blood count showed white blood cell 1.94×10^9^/l, red blood cell 1.90×10^12^/l, haemoglobin 66 g/l, platelet 16×10^9^/l. Bone marrow aspiration revealed a hyperplastic marrow: The granulocytes accounted for 29%, and the myeloblasts accounted for 12.5%; the mononucytes accounted for 32%, and the monoblasts and promonocytes accounted for 21% ([Fig. 3](#f3-ol-0-0-8992){ref-type="fig"}). The blasts were positive for myeloperoxidase stain, and positive for nonspecific esterase, which was inhibited by sodium fluoride. Immunophenotyping of the bone marrow indicated that a group of blast cells (accounting for 4.84%) were positive for CD13, CD34, CD117, HLA-DR and negative for CD7, CD10, CD15, CD19, CD20, CD22, CD33, CD11b, CD14, CD64; another group of blast cells (accounting for 53.6%) were positive for CD13, CD33, CD15, CD64, CD11b, and weak positive for CD10 and CD14. These data are consistent with AML French-American-British (FAB) classification M4 subtype. Chromosome karyotype was 46, XY. Then CAG chemotherapy (aclarubicin hydrochloride, low-dose cytarabine and granulocyte colony-stimulating factor) combined with decitabine were administered accordingly and his condition alleviated. This patient is still being followed.

### Patient demographics

We found greater higher occurrence in men and this was approximately two times more often than in women. The vocal cords and epiglottis are commonly involved and the main symptom is hoarseness often accompanied by dyspnea, dysphagia, and other symptoms. Supraglottic EMP accounted for the majority of patients with cervical lymphadenopathy. Likely this is due to association with lymphatic vascularity in the supraglottis, which is much denser than in the glottis or subglottis, and this causes greater incidence of lymph node metastasis.

### Treatment options

Of 96 recorded treatment modalities, radiotherapy alone was the most common treatment modality, used in 41 cases, followed by a combination of surgery and radiotherapy, and surgery alone. Furthermore, we found that surgically based treatment was the most common treatment modality for cases published in recent years ([Table III](#tIII-ol-0-0-8992){ref-type="table"}), despite there was no statistically significant difference between surgically based treatment and no-surgically based treatment modalities reported in these annual intervals (P=0.65).

### Outcomes and sequelaes

Overall treatment outcome was favorable, as a total of 84% of patients were alive after a mean follow-up of 60 months, independent of treatment modality. However, EMP outcomes for patients with cervical lymphadenopathy or multiple sites involvement were unfavorable, more than 40% with recurrence or metastasis during the limited follow-up period. A total of 21 patients were reported with relapse or metastasis in the clinical course, among which 12 cases were reported that EMP occurred in either multiple sites of the larynx or coexistence with other body sites, and 6 with cervical lymphadenopathy. A total of 6 cases developed MM finally, of which 3 cases occurred in the multiple sites of the larynx, and 2 originated in the supraglottis at the initial visits.

Discussion
==========

EMP of the larynx is an extremely rare plasma cell neoplasm which constitutes less than 0.2% of the malignancies in the larynx ([@b3-ol-0-0-8992],[@b4-ol-0-0-8992]). EMP may occur in various sites of the larynx such as the epiglottis, vocal folds, and subglottis. Clinical symptoms are closely related to the location of tumor and the degree of impairment of laryngeal structure. Laryngeal EMP may present different morphologic forms, sometimes a single, smooth polypoid mass, and sometimes diffuse swelling tissue just like our patient. So it is easily misdiagnosed due to the fact that the clinical symptoms and laryngoscope findings are nonspecific compared with other diseases such as laryngeal lymphoma and tuberculosis. Recently, imaging examination has been used more and more widely. For example, CT and MRI of neck may be used to identify the location of tumor and cervical lymphadenopathy, evaluate the involvement of the adjacent structures and curative effect. PET-CT has been used more and more to understand the nature of the lesion and the existence of the distant metastasis. Although radiological findings have acquired much achievement, diagnosis of EMP mainly relies on histopathologic examination by the presence of monoclonal plasma cell hyperplasia. However, the diagnosis could not be made early sometimes by routine pathological observation alone. Thus, immunohistochemistry and immunophenotype are proposed to make a definitive diagnosis or differential diagnosis, for example, most cells may be positive for CD138, CD38, CD79a, and negative for CD20, CD3 ([@b3-ol-0-0-8992],[@b4-ol-0-0-8992],[@b35-ol-0-0-8992]). Sometimes, immunoglobulin gene rearrangement analysis is also advised to confirm the diagnosis of EMP.

Given that EMPs are radiosensitive, radiotherapy is traditionally used as first-line treatment for solitary EMP ([@b72-ol-0-0-8992]). Similarly, single-modality radiotherapy was the most common treatment modality for laryngeal EMP, followed by a combination of surgery and radiotherapy, and surgery alone in our analysis. Recently, surgically based treatment, including surgical resection either alone or with adjuvant radiotherapy was proposed and proved that it could offer better survival outcomes compared to radiotherapy alone ([@b3-ol-0-0-8992],[@b73-ol-0-0-8992]). In contrast, some studies showed no survival benefit for one treatment modality over another, and even recommended that radical surgery should be avoided for EMP ([@b74-ol-0-0-8992]). So far, the optimal treatment modality for the management of EMP remains controversial. But it has been generally accepted that chemotherapy is not considered to be a first-line therapy option and adjuvant chemotherapy is usually used in patients with disseminated or recurrent disease, that resembles the present case ([@b3-ol-0-0-8992],[@b72-ol-0-0-8992]).

In our review, we found radiotherapy alone was the most common treatment modality for cases published between 1990 and 1999, but for cases reported from 2010 and onward, the most common treatment modality was surgically based treatment. There may be some reasons for the shift toward surgical management of small tumors. On the one hand, surgical techniques advance such as laser excision application for laryngeal microsurgery has made it possible to completely resection of lesion through minimally invasive surgery. On the other hand, patients receiving radiotherapy for head and neck EMP had a higher conversion to MM ([@b3-ol-0-0-8992]), and we found 4 of 6 patients that developed MM received radiotherapy alone in our review, therefore, surgical management of laryngeal EMP should be considered to avoid risk factors for conversion. However, whether it could offer better survival outcomes compared to radiotherapy alone is still to be further studied. Furthermore, patient outcomes may be associated with tumor distribution or cervical lymphadenopathy in addition to treatment modality. For example, more than 40% of patients with cervical lymphadenopathy or multiple sites involvement were reported with recurrence or metastasis, or even died of disease in our review. In summary, patient outcomes may be affected by many aspects, and management of laryngeal EMP should also be considered on a case-by-case basis. Factors such as tumor location; histological grade; regional lymphadenopathy; feasibility of complete resection; laryngeal function; and potential risk of recurrence or conversion to MM should be considered when determining the most suitable treatment modality.

EMPs tend to have more favorable outcomes than solitary bone plasmacytomas or MM, and overall survival for 10 years is estimated to exceed 70% ([@b73-ol-0-0-8992]). We noted that 84% of patients in our analysis were alive after a mean follow-up of 60 months. However, we also found that patients with cervical lymphadenopathy, multiple anatomical regions of the larynx or other organ involvement may be prone to relapse or metastasis. The highest risk of conversion to MM is reported to be in the first 2 years after diagnosis, but conversion has also been noted more than 15 years later ([@b4-ol-0-0-8992]). In our analysis, 3 patients developed MM in the first 2 years, and 1 subject developed MM 12 years later. Although there is debate about high risk factors of conversion to MM, once converted to MM, patients have poor prognosis, and fewer than 10% of patients survive 10 years ([@b3-ol-0-0-8992]). Therefore, progression to MM maybe a poor prognostic factor or a determinant factor for survival. Few patients developed MM in our analysis, and this was less than the expected range. This may be due to the relatively short follow-up for most cases. Therefore, follow-up and regular screening for MM is important.

To the best of our knowledge, this is the first case of laryngeal EMP who subsequently developed AML. On one hand, AML, as the primary second tumor, may occur subsequent to plasma cell myeloma or MM. On the other hand, the occurrence of AML in this case maybe closely related to chemotherapy or radiotherapy, and so it is referred to as therapy-related AML (t-AML). At this time, it is unclear whether this represents an intrinsic predisposition or therapy-related phenomenon ([@b75-ol-0-0-8992]). Similarly, the pathologic procedure and pathogenesis for this case are unclear and must be elucidated. Even so, this unusual case provides evidence that laryngeal EMP may develop therapy-related myeloid neoplasms (t-MNs) even though this is rare.

In conclusion, we present a comprehensive literature review spanning 60 years to increase awareness of laryngeal EMP. Our findings suggest radiotherapy alone is the most common treatment modality, but surgically based treatment has been the most common treatment modality in recent years. EMP localized to a single region of the larynx may have good outcomes. In addition to MM, t-MNs should be considered during the follow-up period. Due to the inherent limitations of this review, further study about optimal treatment modalities should be considered with randomized controlled clinical trials.
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![Fiberoptic laryngoscopic view at first presentation.](ol-16-03-2995-g00){#f1-ol-0-0-8992}

![Histopathological examination of the biopsy specimens. Pathological findings revealed a large amount of plasmocyte and lymphocyte infiltration in the (A) laryngeal tumor tissue and (B) cervical lymph nodes (haemotoxylin and eosin staining, magnification, ×400).](ol-16-03-2995-g01){#f2-ol-0-0-8992}

![Bone marrow aspirate smear revealed myeloid leukemia cells (Wright-Giemsa staining, oil immersion lens; magnification, ×1,000).](ol-16-03-2995-g02){#f3-ol-0-0-8992}

###### 

List of laryngeal EMP cases included in analysis.

  Author, year                      No/sex/age   Primary sites                            Treatment    LR or MET   Follow-up   Outcome   (Refs.)
  --------------------------------- ------------ ---------------------------------------- ------------ ----------- ----------- --------- ----------------------
  The present case                  1/M/46       Epiglottis and aryepiglottic fold        RT + CT      AML         61 ms       AWD       
  Pino *et al*, 2015                2/M/65       Left false cord and ventricle            S + RT       N           54 ms       ANED      ([@b5-ol-0-0-8992])
  Wang *et al*, 2015                3/M/43       Glottis, supraglottis, and subglottis    S            MM          88 ms       AWD       ([@b6-ol-0-0-8992])
  Haser *et al*, 2015               4/M/72       Bilaterally vocal cords and subglottis   RT           N           1 y         ANED      ([@b7-ol-0-0-8992])
  Xing *et al*, 2015                5/F/47       Left aryepiglottic fold                  S + RT       N           18 ms       ANED      ([@b8-ol-0-0-8992])
  Abrari *et al*, 2014              6/M/56       Right vocal cord                         RT           N           NA          ANED      ([@b9-ol-0-0-8992])
  Loyo *et al*, 2013                7/F/80       Right glottis                            S            NA          NA          ANED      ([@b10-ol-0-0-8992])
  Ghatak *et al*, 2013              8/F/29       True vocal cord                          RT           N           16 ms       ANED      ([@b11-ol-0-0-8992])
  Kim *et al*, 2012                 9/M/58       Left arytenoid                           S            N           2 ys        ANED      ([@b12-ol-0-0-8992])
  Pinto *et al*, 2012               10/F/49      Left false fold                          S            N           1 y         ANED      ([@b13-ol-0-0-8992])
  Ramírez-Anguiano *et al*, 2012    11/M/57      Right subglottis                         S + RT       Y           1 y         ANED      ([@b14-ol-0-0-8992])
  De Zoysa *et al*, 2012            12/F/62      Left true vocal fold                     RT           N           2 ms        ANED      ([@b15-ol-0-0-8992])
  Pichi *et al*, 2011               13/M/73      Left glottis and subglottis              RT           MM          2 ys        DOD       ([@b16-ol-0-0-8992])
  Zhang *et al*, 2010               14/W/56      Left false vocal cord and ventricle      S            N           2 ys        ANED      ([@b17-ol-0-0-8992])
  González Guijarro *et al*, 2010   15/M/11      Right hemilarynx                         S + RT       N           3 ys        ANED      ([@b18-ol-0-0-8992])
  Vanan *et al*, 2009               16/F/16      Right vocal cord                         RT           N           1 y         ANED      ([@b19-ol-0-0-8992])
  Pratibha *et al*, 2009            17/M/49      False vocal cord, vocal cord             RT           N           6 ms        ANED      ([@b20-ol-0-0-8992])
  Iseri *et al*, 2009               18/F/46      Aryepiglottic fold                       S + RT +CT   N           2 ys        ANED      ([@b21-ol-0-0-8992])
  Rutherford *et al*, 2009          19/F/13      Subglottis, nasopharynx                  S + RT       N           6 weeks     ANED      ([@b22-ol-0-0-8992])
  Ozbilen Acar *et al*, 2008        20/F/43      True vocal cord                          S            N           2 ys        ANED      ([@b23-ol-0-0-8992])
  Straetmans and Stokroos, 2008     21/M/57      Epiglottis                               S + RT       Y           27 ms       ANED      ([@b1-ol-0-0-8992])
  Velez *et al*, 2007               22/M/64      Right hemilarynx                         S + RT       N           3 ys        ANED      ([@b24-ol-0-0-8992])
  Kusunoki *et al*, 2007            23/F/76      Supraglottis                             Biopsy       N           6 ms        AWD       ([@b25-ol-0-0-8992])
  Lewis *et al*, 2007               24/M/71      Supraglottis, soft palate                S            N           2 ys        ANED      ([@b26-ol-0-0-8992])
  Nakashima *et al*, 2006           25/M/39      Left arytenoid                           S + RT       N           6 ys        ANED      ([@b27-ol-0-0-8992])
                                    26/M/59      Epiglottis                               S            N           15 ys       ANED      
  Sakiyama *et al*, 2005            27/F/47      Subglottis, the chest wall               RT + CT      N           7 ys        ANED      ([@b28-ol-0-0-8992])
  Chao *et al*, 2005                28/M/60      Supraglotis                              RT           N           37 ms       DOC       ([@b29-ol-0-0-8992])
  Yavas *et al*, 2004               29/F/43      Left vocal cord, nasopharynx             RT           NA          NA          NA        ([@b30-ol-0-0-8992])
  Michalaki *et al*, 2003           30/F/46      Larynx                                   RT           N           49 ms       ANED      ([@b31-ol-0-0-8992])
                                    31/M/59      Larynx                                   RT           N           67 ms       ANED      
  Soni *et al*, 2002                32/M/65      Subglottis                               RT           N           2 ys        ANED      ([@b32-ol-0-0-8992])
  Kamijo *et al*, 2002              33/M/84      False vocal fold                         S + RT       N           2 years     ANED      ([@b33-ol-0-0-8992])
  Strojan *et al*, 2002             34/M/65      Left false vocal cord                    RT           N           7.8 years   DOC       ([@b34-ol-0-0-8992])
  Strojan *et al*, 2002             35/M/72      Right true vocal cord                    S + RT       N           4.7 ys      DOC       
                                    36/F/50      Right glottis                            RT           N           2.2 ys      ANED      
  Nagasaka *et al*, 2001            37/F/12      Right subglottis                         S + RT       N           4 ys        ANED      ([@b35-ol-0-0-8992])
  Maheshwari *et al*, 2001          38/M/65      Subglottis                               RT           N           12 ms       ANED      ([@b36-ol-0-0-8992])
  Uppal and Harrison, 2001          39/M/54      Left hemilarynx                          RT           MM          weeks       DOD       ([@b37-ol-0-0-8992])
  Rakover *et al*, 2000             40/M/38      Right true vocal fold                    S + RT       N           3 ys        ANED      ([@b38-ol-0-0-8992])
  Hotz *et al*, 1999                41/NA/63     Larynx, nasopharynx, nasal fossa         S + RT       N           108 ms      ANED      ([@b39-ol-0-0-8992])
                                    42/NA/45     Larynx, nasopharynx                      S + RT       Y           108 ms      AWD       
  Alexiou, 1999                     43/M/69      Larynx                                   S            N           62 ms       ANED      ([@b3-ol-0-0-8992])
                                    44/M/40      Aryepiglottic fold                       S + RT       N           20 ms       ANED      
  Nowak-Sadzikowska and Weiss,      45/M/34      Supraglottis                             RT           N           10 ys       ANED      ([@b40-ol-0-0-8992])
  1998                              46/M/50      Glottis                                  RT           N           10 ys       ANED      
                                    47/M/36      Supraglottis                             RT           N           10 ys       ANED      
                                    48/F/68      Supraglottis                             RT           N           10 ys       ANED      
                                    49/M/48      Glottis                                  RT           N           10 ys       ANED      
  Bhattacharya *et al*, 1998        50/F/49      Supraglottis                             Biopsy       N             6 ms      DOC       ([@b41-ol-0-0-8992])
  Sulzner *et al*, 1998             51/M/49      Right aryentoid                          RT           N           5 ys        ANED      ([@b42-ol-0-0-8992])
  Susnerwala, 1997                  52/F/79      Larynx                                   RT           N           132 ms      ANED      ([@b2-ol-0-0-8992])
                                    53/M/65      Larynx                                   RT           N           52 ms       ANED      
  Rolins *et al*, 1995              54/M/43      Epiglottis                               S            N           3 ys        ANED      ([@b43-ol-0-0-8992])
  Mochimatsu *et al*, 1993          55/M/42      Epiglottis                               S + RT       MM          12 ys       DOD       ([@b44-ol-0-0-8992])
  Weissman *et al*, 1993            56/M/76      Subglotis                                S + RT       NA          NA          NA        ([@b45-ol-0-0-8992])
  Barbu *et al*, 1992               57/M/69      Supraglottis                             RT           N           3 ys        ANED      ([@b46-ol-0-0-8992])
  Kost *et al*, 1990                58/M/43      Left vocal cord                          RT           NA          NA          NA        ([@b47-ol-0-0-8992])
  Gambino, 1988                     59/M/47      Epiglottis                               S + RT       NA          NA          NA        ([@b48-ol-0-0-8992])
  Gaffney *et al*, 1987             60/M/80      Larynx                                   RT           N           7 ms        ANED      ([@b49-ol-0-0-8992])
  Burke *et al*, 1986               61/M/53      Supraglottis, and mouth                  CT           N           1 y         ANED      ([@b50-ol-0-0-8992])
  Gadomski *et al*, 1986            62/F/54      Bilateral true vocal cords               S + CT       N           15 ys       DOC       ([@b51-ol-0-0-8992])
                                    63/F/51      Right aryeplottic fold                   RT           N           5 ys        ANED      
  Maniglia and Xue, 1983            64/F/64      Hemilarynx                               S + RT       N           1 y         DOC       ([@b52-ol-0-0-8992])
  Bjelkenkrantz *et al*, 1981       65/NA        Right false vocal cord, left tonsil      S + RT       N           7 ys        ANED      ([@b53-ol-0-0-8992])
  Bush *et al*, 1981                66/F/52      Epiglottis, supraorbital region          RT           N           3 ys        DOC       ([@b54-ol-0-0-8992])
                                    67/F/34      Larynx                                   S + RT       Y           5.9 ys      ANED      
  Singh, *et al* 1979               68/F/42      Supraglottis                             S + RT       N           29 ms       ANED      ([@b55-ol-0-0-8992])
  Woodruff *et al*, 1979            69/F/64      Supraglottis                             RT           N           6.5 ys      DOC       ([@b56-ol-0-0-8992])
                                    70/F/34      Supraglottis                             RT           N           Recently    ANED      
  Petrovich *et al*, 1977           71/M/74      Epiglottis                               RT           N           6 ys        ANED      ([@b57-ol-0-0-8992])
  Gorenstein *et al*, 1977          72/M/58      Right true vocal cord                    S + RT       N           3 ys        ANED      ([@b58-ol-0-0-8992])
                                    73/M/63      Right true vocal cord                    S + RT       N           25 ys       ANED      
                                    74/M/59      Subglottis                               S            N           5 ys        DOC       
                                    75/M/32      Subglottis                               S            N           10 ys       ANED      
                                    76/M/42      Bilateral true cords                     S            N           5 ys        ANED      
                                    77/M/61      Supraglottis                             RT           N           6 ys        ANED      
  Muller and Fisher, 1976           78/M/44      Supraglottis                             Biopsy       NA          NA          AWD       ([@b59-ol-0-0-8992])
  Fishkinand Spiegelberg, 1976      79/M/74      Right epiglottis                         RT           Y           4 ys        AWD       ([@b60-ol-0-0-8992])
  Stone and Cole, 1971              80/M/67      Left false vocal fold                    RT + CT      N           10 ms       ANED      ([@b61-ol-0-0-8992])
  Poole and Marchetta, 1968         81/M/41      Larynx, multiple sites at autopsy        S + RT       Y           3 ys 5 ms   DOD       ([@b62-ol-0-0-8992])
  Webb, 1962                        82M/62       Left supraglottis, soft palate           RT           MM          10 ys       DOD       ([@b63-ol-0-0-8992])
                                    83/F/55      Right vocal cord and ventricle           S            N           11 ys       ANED      
                                    84/M/32      Subglottis                               S + RT       N           10 ys       ANED      
  Dolin and Dewar, 1956             85/M/74      Larynx                                   RT           N           3.5 ys      DOC       ([@b64-ol-0-0-8992])
                                    86/M/73      Larynx                                   S            N           1 y         ANED      
                                    87/M/59      Larynx                                   RT           N           4 ys        ANED      
  Priest, 1952                      88/M/50      Larynx, pharynx, and nose                S            Y           4 ys        AWD       ([@b65-ol-0-0-8992])
  Ewing and Foote, 1952             89/M/76      Larynx                                   RT           N           6 ms        AWD       ([@b66-ol-0-0-8992])
  Costen, 1951                      90/M/52      Left epiglottis                          RT           MM          1 y         AWD       ([@b67-ol-0-0-8992])
  Rawson *et al*, 1950              91/F/59      Larynx                                   S + RT       Y           11 ys       AWD       ([@b68-ol-0-0-8992])
  Stout and Kenney, 1949            92/M/46      Left epiglottis, oropharynx              S            Y           14 ys       ANED      ([@b69-ol-0-0-8992])
                                    93/F/67      Epiglottis                               RT           Y           6 ms        DOD       
                                    94/NA        Larynx, nasopharynx and conjunctiva      S            Y           3 ys        AWD       
                                    95/M/64      Larynx, nasopharynx                      S            Y           2 ys        AWD       
                                    96/F/48      Larynx, nasopharynx, and nasal cavity    S            Y           11 ys       AWD       
  Hodge and Wilson, 1948            97/M/53      Left false vocal cord                    S            N           1 y         ANED      ([@b70-ol-0-0-8992])
  Lumb and Prossor, 1948            98/M/34      Larynx                                   RT           Y           30 ms       AWD       ([@b71-ol-0-0-8992])
                                    99/M/20      Larynx, palate, and tongue               S + RT       Y           7 ys 6 ms   AWD       

EMP, extramedullary plasmacytoma; M, male; F, female; RT, radiotherapy; S, surgery; CT, chemotherapy; LR, Local recurrence; MET, metastasis; MM, multiple myeloma; AML, acute myeloid leukemia; ys, years; ms, months; AWD, alive with disease; ANED, alive, no evidence of disease; DOD, died of disease; DOC, died of other causes; Y, yes; N, no; NA, not acquired.

###### 

Clinical features of included cases.

  Characteristics (n=95)                        Measure, n (% total)
  --------------------------------------------- ----------------------
  Patient age, mean, median (range), years      53.3, 54 (11--80)
    Male, mean (n=65)                           54.9
    Female, mean (n=30)                         50
  Symptoms (n=67)                               
    Hoarseness                                  46 (69)
    Dysphonia                                   7 (10)
    Dyspnea                                     13 (19)
    Dysphagia                                   9 (13)
    Stridor                                     6 (9)
    Cough                                       6 (9)
    Sore throat                                 3 (4)
    Hemoptysis                                  3 (4)
    Laryngeal foreign body sensation            3 (4)
  Laterality (n=41)                             
    Right                                       19 (46)
    Left                                        17 (41)
    Both                                        5 (12)
  Primary site (n=79)                           
    Glottis                                     19 (24)
    Supraglottis                                41 (52)
      Epiglottis                                12 (15)
      Aryepiglottic fold                        4 (5)
      Arytenoid                                 3 (4)
      False vocal cord                          8 (10)
      Multiple sites                            2 (3)
      Unknown detailed site                     12 (15)
    Subglottis                                  10 (13)
    Hemilarynx or 2--3 parts of the larynx      9 (11)
  Cervical lymph nodes involvement (n=12)       
    Glottic patient                             1 (8)
    Supraglottic patient                        8 (67)
    Hemilaryngeal patient                       1 (8)
  Coexistence with other body sites involved    17
  Treatment (n=96)                              
    Radiotherapy alone                          41 (43)
    Surgery alone                               21 (22)
    Chemotherapy alone                          1 (1)
    Surgery and radiotherapy                    28 (29)
    Radiotherapy and chemotherapy               3 (3)
    Surgery and chemotherapy                    1 (1)
    Radiotherapy, surgery, and chemotherapy     1 (1)
  Radiotherapy dose, mean, median (range), Gy   49.6, 50 (30--70)
  No treatment (n=3)                            
  Follow-up, mean, median (range), ms (n=90)    60, 45 (1.5--300)
    Recurrence or metastasis                    21 (23)
    No recurrence or metastasis                 69 (77)
    MM                                          6 (7)
    AML                                         1 (1)
  Outcome (n=91)                                
    ANED                                        63 (69)
    AWD                                         13 (14)
    DOD                                         6 (7)
    DOC                                         9 (10)

ms, months; MM, multiple myeloma; AML, acute myeloid leukaemia; ANED, alive, no evidence of disease; AWD, alive with disease; DOD, died of disease; DOC, died of other causes.

###### 

Treatment modalities by annual interval.

                                      Years                          
  ----------------------------------- --------- ---------- --------- --------
  Surgically based treatment (%)      22 (55)     7 (41)   11 (46)   9 (60)
  No-surgically based treatment (%)   18 (45)   10 (59)    13 (54)   6 (40)
